This page shows the latest uterine fibroids news and features for those working in and with pharma, biotech and healthcare.
The lead candidate from the endometriosis alliance is vilaprisan, which has advanced into phase 2 trials in both endometriosis and uterine fibroids but suffered a setback at the end of 2018,
Myovant is in a head-to-head battle with AbbVie and its rival GnRH inhibitor Orilissa (elagolix) in endometriosis-related pain and uterine fibroids, but has a clear run at the ... cancer”. It’s also an important development as Myovant has delayed
Will face competition from Myovant rival. AbbVie is gunning for the second indication for its new women’s health product Orilissa, hoping to add uterine fibroids to its FDA approval last ... That raises the question of whether women will be prepared to
and was due to be filed for the uterine fibroids indication right about now, giving it a few months’ head start. ... Analysts suggest that uterine fibroids could be a $1bn-plus market for GnRH antagonists.
Uterine fibroids are non-cancerous tumours that form in the muscle walls of the uterus and affect between 20% and 80% of women by the age of 50. ... Their drug is already approved as Orilissa to treat endometriosis and has two positive phase 3 readouts
Others cued up for results include phase 3 trials of Myovant’s relugolix in uterine fibroids, endometriosis and prostate cancer, and Dermavant’s tapinarof in psoriasis.
More from news
Approximately 5 fully matching, plus 23 partially matching documents found.
Dr. Charlotte Owens, an OB-GYN and medical director of AbbVie, has completed successful clinical trials on uterine fibroids with a high representation of Black women, and outlines the key steps
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...